Ghent, BELGIUM – 26 August 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its half year results ended 30 June 2021 on Thursday, 2 September 2021. The management team will host a conference...Read More